Clinical trials: CDK4/6 Inhibitor
Metastatic Breast Cancer
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment…
- Trial name
- NCT06377852
- Testing
- Palbociclib 125mg, Ribociclib 600mg, Ribociclib
- Where
- 88 sites in United States
- Volunteers
- 500 people
- Sponsor
- American Society of Clinical Oncology
Breast Cancer
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment.
- Trial name
- NCT02657343
- Testing
- Ribociclib, T-DM1, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute